Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025

Reuters

06-10

Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025

Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542538823"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542538823\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542538823?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542538823","market":"nz","top_or_hot":-1,"title":"Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-10 06:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL84Mnbj:1","article_id":"2542538823","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542538823","pubTimestamp":1749506426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav  oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies . The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"Jazz Pharmaceuticals公布了Xywav®的最新4期数据：2025年睡眠中发作性睡病治疗的新见解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n    \n\n        Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}